ASCO 2022 | Advancing cancer therapeutics for brain metastases

Bently Doonan, MD, University of Florida, Gainesville, FL, talks on the advances in the field of HER2 breast cancer brain metastases and the survival benefit due to the developments in brain penetrating treatments. As duration of response increases with advances in cancer therapeutics, the number of patients developing brain metastases will also increase. Dr Doonan therefore emphasizes the significance of advancing therapeutics for the treatment of brain metastases. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.